Jae Ryung Lee1, Jong-Lyel Roh2, Sun Mi Lee3, Yangsoon Park3, Kyung-Ja Cho3, Seung-Ho Choi1, Soon Yuhl Nam1, Sang Yoon Kim1. 1. Department of Otolaryngology, Asan Medical Centre, University of Ulsan College of Medicine, 88 Olympic-ro, 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. 2. Department of Otolaryngology, Asan Medical Centre, University of Ulsan College of Medicine, 88 Olympic-ro, 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. rohjl@amc.seoul.kr. 3. Department of Pathology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Abstract
PURPOSE: Intracellular antioxidant enzymes are commonly upregulated in various cancer types and are associated with treatment outcomes. Because the relationship has rarely been examined in oral squamous cell carcinoma (OSCC), we aimed to evaluate the association between the levels of glutathione peroxidase (GPX)1, GPX4, and thioredoxin reductase (TrxR)1 expression and prognosis in patients with OSCC who underwent curative surgical resection. METHODS: This study included 233 patients who underwent curative surgery for previously untreated OSCC between 2000 and 2012. Tumour GPX1, GPX4, and TrxR1 expression was evaluated by immunohistochemistry and was dichotomised to low and high values according to defined expression levels. The association between GPX1, GPX4, and TrxR1 expression and clinicopathological results was analysed. Univariate and multivariate analyses using the Cox proportional hazards model were conducted to assess the significance of differences in recurrence or survival outcomes between variables. RESULTS: High GPX1, GPX4, and TrxR1 expression was observed in 99 (42.5%), 133 (57.1%), and 46 (19.7%) patients, respectively. GPX1 overexpression was significantly correlated with nodal metastasis, advanced overall stage, depth of invasion of >10 mm, high grade and perineural invasion (P < 0.05). High GPX4 expression was also related to nodal metastasis, overall advanced stage and high grade (P < 0.05). Univariate and multivariate analyses showed that increased GPX1 expression was significantly associated with poor disease-free, cancer-specific and overall survival (all P < 0.05), while increased GPX4 or TrxR1 expression was not (all P > 0.1). CONCLUSIONS: Tumour GPX1 expression is a useful biomarker predictive of recurrence and survival in OSCC patients.
PURPOSE: Intracellular antioxidant enzymes are commonly upregulated in various cancer types and are associated with treatment outcomes. Because the relationship has rarely been examined in oral squamous cell carcinoma (OSCC), we aimed to evaluate the association between the levels of glutathione peroxidase (GPX)1, GPX4, and thioredoxin reductase (TrxR)1 expression and prognosis in patients with OSCC who underwent curative surgical resection. METHODS: This study included 233 patients who underwent curative surgery for previously untreated OSCC between 2000 and 2012. Tumour GPX1, GPX4, and TrxR1 expression was evaluated by immunohistochemistry and was dichotomised to low and high values according to defined expression levels. The association between GPX1, GPX4, and TrxR1 expression and clinicopathological results was analysed. Univariate and multivariate analyses using the Cox proportional hazards model were conducted to assess the significance of differences in recurrence or survival outcomes between variables. RESULTS: High GPX1, GPX4, and TrxR1 expression was observed in 99 (42.5%), 133 (57.1%), and 46 (19.7%) patients, respectively. GPX1 overexpression was significantly correlated with nodal metastasis, advanced overall stage, depth of invasion of >10 mm, high grade and perineural invasion (P < 0.05). High GPX4 expression was also related to nodal metastasis, overall advanced stage and high grade (P < 0.05). Univariate and multivariate analyses showed that increased GPX1 expression was significantly associated with poor disease-free, cancer-specific and overall survival (all P < 0.05), while increased GPX4 or TrxR1 expression was not (all P > 0.1). CONCLUSIONS: Tumour GPX1 expression is a useful biomarker predictive of recurrence and survival in OSCC patients.
Authors: Gitte Ravn-Haren; Anja Olsen; Anne Tjønneland; Lars O Dragsted; Bjørn A Nexø; Håkan Wallin; Kim Overvad; Ole Raaschou-Nielsen; Ulla Vogel Journal: Carcinogenesis Date: 2005-11-14 Impact factor: 4.944
Authors: Arancha Cebrian; Paul D Pharoah; Shahana Ahmed; Paula L Smith; Craig Luccarini; Robert Luben; Karen Redman; Hannah Munday; Douglas F Easton; Alison M Dunning; Bruce A J Ponder Journal: Cancer Res Date: 2006-01-15 Impact factor: 12.701
Authors: T Mochizuki; S Furuta; J Mitsushita; W H Shang; M Ito; Y Yokoo; M Yamaura; S Ishizone; J Nakayama; A Konagai; K Hirose; K Kiyosawa; T Kamata Journal: Oncogene Date: 2006-03-13 Impact factor: 9.867
Authors: Zachary T Schafer; Alexandra R Grassian; Loling Song; Zhenyang Jiang; Zachary Gerhart-Hines; Hanna Y Irie; Sizhen Gao; Pere Puigserver; Joan S Brugge Journal: Nature Date: 2009-08-19 Impact factor: 49.962
Authors: Julia A Knight; U Venus Onay; Sean Wells; Hong Li; Ellen J Q Shi; Irene L Andrulis; Hilmi Ozcelik Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-01 Impact factor: 4.254
Authors: Steven Behnisch-Cornwell; Siva Sankar Murthy Bandaru; Martin Napierkowski; Lisa Wolff; Muhammad Zubair; Claudia Urbainsky; Christopher Lillig; Carola Schulzke; Patrick J Bednarski Journal: ChemMedChem Date: 2020-05-06 Impact factor: 3.466
Authors: Jie Zhao; Wanbiao Chen; Yi Pan; Yinfeng Zhang; Huiying Sun; Han Wang; Fan Yang; Yu Liu; Nan Shen; Xuan Zhang; Xi Mo; Jianye Zang Journal: Sci Adv Date: 2021-06-18 Impact factor: 14.136